SCHEMBL4707647

SCHEMBL4707647

CC(=O)c1c(-c2ccccc2)nn(Cc2ccncc2)c(=O)c1Nc1cc(F)cc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.55
PTGDR2 Q9Y5Y4 1/20 0.41
HTR1A P08908 2/20 0.40
ADRA1D P25100 2/20 0.40
ADRA1A P35348 2/20 0.40
ADRA1B P35368 2/20 0.40
ADORA2A P29274 5/20 0.40
ADORA1 P30542 5/20 0.40
ALDH1A1 P00352 2/20 0.40
CSF1R P07333 1/20 0.38
FGFR1 P11362 1/20 0.38
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38
CSNK1A1 P48729 1/20 0.38
CDK8 P49336 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
CDK5 Q00535 1/20 0.38
PRKCQ Q04759 1/20 0.38
LRRK2 Q5S007 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4706954 0.94 PDE4B (0.58) PDE4BPTGDR2HTR1AADRA1DADRA1A
SCHEMBL4705588 0.93 PDE4B (0.53) PDE4BPTGDR2HTR1AADRA1DADRA1A
SCHEMBL4706078 0.87 PDE4B (0.56) PDE4BPTGDR2HTR1AADRA1DADRA1A
SCHEMBL4705746 0.86 PDE4B (0.72) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4707420 0.86 PDE4B (0.54) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL6169312 0.83 PDE4B (0.65) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4706403 0.82 PDE4B (0.56) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4707235 0.81 CSF1R (0.56) PDE4BHTR1AADRA1DADRA1AADRA1B
SCHEMBL4707081 0.80 PDE4B (0.49) PDE4BADORA2AADORA1ALDH1A1PDE4A
SCHEMBL1654205 0.80 PDE4B (0.78) PDE4BHTR1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885PTGDR2 153/4885HTR1A 1051/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885PTGDR2 153/4885HTR1A 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.